Novel miR-451/ETV4/MMP13 signaling axis identified as key driver of non-small cell lung cancer progression
FAR Publishing Limited
A groundbreaking study published in Current Molecular Pharmacology has uncovered a pivotal signaling pathway driving non-small cell lung cancer (NSCLC) progression. Led by Dr. Xi Yu and colleagues at Tianjin First Central Hospital, the research demonstrates how the miR-451/ETV4/MMP13 axis orchestrates tumor growth and metastasis through epithelial-mesenchymal transition (EMT).
Analyzing 108 NSCLC patient tissues, the team found miR-451 levels plummeted in tumors, while ETV4 and MMP13 surged—correlating with advanced TNM stages and poor prognosis. "Our data reveal miR-451 as a tumor suppressor that, when lost, unleashes ETV4-MMP13 to fuel NSCLC aggression," Dr. Yu explained.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.